Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099736 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
NCT00099736: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00099736 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 696 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099736, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
Study Summary
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
Interventions
- DRUG FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
- DRUG FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
- DRUG MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2003-05-07 |
| Est. Completion | 2005-09-19 |
| Phase | Phase 3 |
What the finished NCT00099736 record still lists
NCT00099736 is an interventional study that assigns participants to a tested intervention. The registered 696 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 3 interventions - of which FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids is the first listed.
NCT00099736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00099736 about?
NCT00099736 is a clinical study titled "Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant". The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
What is the current status of trial NCT00099736?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2003-05-07. Estimated completion is 2005-09-19.
What interventions are being tested in trial NCT00099736?
The interventions under investigation include: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids (DRUG), FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids (DRUG), MMF 2 g + full-dose Neoral (FDN) + corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00099736?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00099736's enrollment target sits among peer trials
696 518th of 2000 higher than 1,483 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI